Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts

Affimed (NASDAQ:AFMD) has been given an average rating of “Moderate Buy” by the five research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $13.50.

AFMD has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Stifel Nicolaus reduced their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. Wells Fargo & Company lowered their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a report on Tuesday, December 10th.

Affimed Trading Down 0.9 %

Shares of Affimed stock opened at $2.13 on Tuesday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 1 year low of $2.02 and a 1 year high of $8.95. The firm’s 50-day moving average is $3.06 and its 200 day moving average is $4.16.

Hedge Funds Weigh In On Affimed

Institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. boosted its stake in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Intellectus Partners LLC lifted its position in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares in the last quarter. FMR LLC grew its holdings in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the period. Jane Street Group LLC purchased a new stake in Affimed in the third quarter worth about $44,000. Finally, Choreo LLC bought a new position in shares of Affimed in the second quarter worth about $54,000. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.